Sec Rises on News of Full-Scale Development of "Flash Cancer Therapy Device"... Market Leadership Anticipated

Sec is showing strong performance on the news that the company has officially begun developing a next-generation cancer treatment technology known as the "Flash Radiation Therapy Device."

As of 1:18 p.m. on April 29, Sec was trading at 13,980 won, up 4.56% from the previous day.

Sec announced that it has signed a multilateral memorandum of understanding (MOU) with the Korea Research Institute of Standards and Science (KRISS), Seoul National University Hospital, Korea Institute of Radiological & Medical Sciences, and Dongnam Institute of Radiological & Medical Sciences to establish a cooperative system for the development and preclinical research of the Flash Radiation Therapy Device.

Flash radiation therapy is a technique that delivers ultra-high doses of radiation in less than one second. It is considered a next-generation cancer treatment method because it significantly shortens treatment time and minimizes damage to healthy tissue. The global market is also still in its early stages, with technological competition intensifying.

Under this agreement, Sec is the only corporate participant and plans to lead commercialization by developing core equipment such as electron beam accelerators and irradiation systems using its own technology. The company aims to secure both technological independence and profitability by internalizing everything from key components to the entire system.

The company stated that it will pursue phased development with the goal of completing preclinical trials and establishing a foundation for clinical entry by 2030.

This content was produced with the assistance of AI translation services.